"CZ - \u010Cesk\u00E1 republika" . . . "203;206" . . "Immunotherapy of HPV-16-associated tumours with tumour cell line/dendritic cell line (TC-1/DC2.4) hybrid vaccines."@en . "[95444869C19D]" . "2003" . "RIV/68378050:_____/03:23033176!RIV/2004/AV0/A23004/N" . "RIV/68378050:_____/03:23033176" . . "Immunotherapy of HPV-16-associated tumours with tumour cell line/dendritic cell line (TC-1/DC2.4) hybrid vaccines." . . . "Jandlov\u00E1, T\u00E1\u0148a" . . "Bieblov\u00E1, Jana" . "Immunotherapy of HPV-16-associated tumours with tumour cell line/dendritic cell line (TC-1/DC2.4) hybrid vaccines."@en . "Immunotherapy of HPV-16-associated tumours with tumour cell line/dendritic cell line (TC-1/DC2.4) hybrid vaccines." . . "49" . "HPV16; dendritic cells; fusion"@en . . "0015-5500" . . . "Folia Biologica" . . "4"^^ . . . "609842" . "\u0160\u00EDmov\u00E1, Jana" . "Hybridization of established dendritic cell lines with tumour cells represents a prospective technology for the construction of antitumour vaccines. Experiments were designed to examine whether administration of cell populations prepared by fusion of HPV 16-associated tumour TC-1 cells with dendritic cell line DC2.4 could be used for treatment of TC-1 tumours growing in syngeneic mice. The therapeutic potency of TC-1/DC2.4 fusion vaccine administered 24 h after fusion and that of TC-1/DC2.4 hybrid cells selected for 3 weeks in HAT-containing medium was tested. It has been found that administration of both types of fusion vaccines at the site of growing TC-1 tumour transplants significantly inhibited tumour growth with regard to the percentage of tumour-bearing mice and to the size of the transplanted tumours. Peritumoral administration of the DC2.4 cells alone also reduced the size of growing TC-1 tumours, but not the percentage of the tumour-bearing mice. Although in the groups of mice treated with f"@en . "4"^^ . "0"^^ . . "0"^^ . "Buben\u00EDk, Jan" . . . "4"^^ . "Z(AV0Z5052915)" . "Hybridization of established dendritic cell lines with tumour cells represents a prospective technology for the construction of antitumour vaccines. Experiments were designed to examine whether administration of cell populations prepared by fusion of HPV 16-associated tumour TC-1 cells with dendritic cell line DC2.4 could be used for treatment of TC-1 tumours growing in syngeneic mice. The therapeutic potency of TC-1/DC2.4 fusion vaccine administered 24 h after fusion and that of TC-1/DC2.4 hybrid cells selected for 3 weeks in HAT-containing medium was tested. It has been found that administration of both types of fusion vaccines at the site of growing TC-1 tumour transplants significantly inhibited tumour growth with regard to the percentage of tumour-bearing mice and to the size of the transplanted tumours. Peritumoral administration of the DC2.4 cells alone also reduced the size of growing TC-1 tumours, but not the percentage of the tumour-bearing mice. Although in the groups of mice treated with f" . .